Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-HSD in MASH
NCT05519475Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Apr 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of rapirosiran in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Regeneron Pharmaceuticals. Started Feb 2023; status: recruiting.
02
Drugs
rapirosiran
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT05519475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519475.